How to Determine Medical Device Classification for Overseas Registration of Imaging Equipment?

Key Summary

Learn how to correctly determine the regulatory classification of imaging devices for overseas registration, including key steps, evidence requirements, common pitfalls, and expert recommendations from AIMEILI.

Executive Summary

The first step in overseas registration of imaging devices is not to prepare technical files directly, but to determine how the target country classifies the product. Classification determines the registration pathway, review timeline, local representative requirements, and whether clinical evaluation is needed. Companies should start with target-country regulations to confirm whether the product qualifies as a medical device, then determine the classification based on risk level and intended use. For GHWP member states or markets in Southeast Asia, the Middle East, Latin America, and other regions, the international classification framework is generally referenced, but differences remain across countries. When determining classification, evidence such as product description, intended use, technical parameters, environment of use, energy source, and invasiveness should be prepared, while cross-referencing domestic NMPA, CE, or FDA classifications. Common risks include neglecting differences in classification standards, copying domestic classifications, underestimating risk escalation due to software or AI features, and not considering the classification of combination devices. Companies should consult local representatives or regulatory consultants early, establish a classification justification dossier, and clearly document the classification basis to avoid late corrections or path changes. Classification judgments also affect labeling content, post-market surveillance requirements, and renewal strategies, so sufficient time should be invested early to create a traceable classification decision record.

Applicable Scenarios and Core Questions

Classification determination for overseas registration of imaging devices is the first regulatory fork in the road for companies entering GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets. Imaging devices covered include X-ray machines, CT, MRI, ultrasound, endoscopes, nuclear medicine imaging systems, and accompanying software. Classification is not just filling out a form; it directly determines whether the subsequent registration will follow an equivalence pathway, substantial equivalence, or full review, whether local clinical trials are required, and who will act as the applicant.

Many companies check whether a similar product has been registered in the target country or directly copy the NMPA classification. This approach often fails because risk definitions vary by country. For example, the same diagnostic ultrasound device might be Class A in one country but Class B or Class II in another. The core question in classification judgment is how the target country's regulatory authority interprets the product's intended use, mechanism of action, target population, and environment of use.

Companies need to answer four questions:

First, is the product defined as a medical device in the target country, or is it excluded from the definition, such as certain pure software or wellness devices?
Second, what is the risk class of the product – low, medium, or high – and does it involve implantation, long-term use, or life support?
Third, which registration pathway applies: self-declaration, simplified registration, full registration, or pre-market approval?
Fourth, is a local representative or authorized representative required, and must the certificate be held by a local entity?

The answers come from the product itself and the target country's regulatory framework. Therefore, companies should not rely only on sales department judgment; a decision team composed of regulatory affairs, R&D engineers, quality leaders, and the local representative should complete the classification assessment before project initiation.

Classification Determination Logic

For classification of imaging devices for overseas registration, it is recommended to follow the logical sequence below without skipping any step.

First, confirm whether the product qualifies as a medical device in the target country. This step is often overlooked but is critical. Some countries may not regulate image-processing software, cloud-based diagnostic systems, or cameras intended for health monitoring as medical devices, but instead as general software or wellness products. If classified incorrectly, companies may perform unnecessary registration work or face non-compliance due to missed registration.

Second, determine the risk class according to the target country's official classification rules. Most countries use a risk-based framework, with grading based on factors such as whether the product is invasive, whether it uses energy, whether it emits radiation, and whether it affects patient safety. Companies should compare the target country's classification rule table to find the most appropriate product category. For multi-country registrations, record the classification rule and basis used in each country separately.

Third, assess the reusability of existing market documentation. If the product already holds an NMPA registration certificate, CE certificate, or FDA marketing authorization, companies can reference these documents during classification determination but cannot directly copy the classification. For example, a CE Class IIa ultrasound device may be classified as Class B in some Southeast Asian countries, but the intended use description must be rewritten locally, not simply pasted from the CE file.

Fourth, confirm the registration pathway and applicant entity. The classification result determines whether registration documents are submitted to a competent authority or a notified body, and whether a local representative is required. In countries without a local entity, most regulations require a local agent or authorized representative to act as the registration applicant. Classification decisions must be confirmed together with the local agent to avoid later changes in representation that could affect certificate control.

For multi-country registrations, companies should also consider using the coordination framework under GHWP, modularizing technical files and then performing local conversion. For example, product basic information, risk management, performance verification, and clinical evaluation modules can be prepared as reusable files, with formats and languages adjusted to each target country's requirements.

Documentation and Evidence

Classification determination is not based on experience alone; it requires a set of traceable evidence documents. At a minimum, the following materials should be prepared to support classification:

Product instructions and user manuals, including intended use, target population, environment of use, and retained in multilingual versions.
Technical parameter sheets, including device type, imaging modality, whether ionizing radiation is emitted, whether invasive, and whether software functions are included.
Risk management reports describing potential risks, risk control measures, and residual risks.
Registration certificates or classification determinations from major global markets for cross-comparison.
Labels and packaging samples, including product name, model, and warning symbols.
Qualification documents and authorization agreements for the local agent or authorized representative.

If the target country's classification rules are unclear, companies may submit a pre-classification application or inquiry letter to ask the regulatory authority about the classification of a specific product. This is feasible in some countries but requires time. Another common practice is to reference classification decisions from neighboring or regional markets, but note that regulatory interpretations may differ among countries.

Companies should also prepare a classification justification memorandum documenting the regulatory provisions, product characteristics, reference documents, and final conclusions used in the classification process. This memorandum is often reviewed by assessors during evaluation and can prove the reasonableness of the original classification during post-market changes.

Common Mistakes

Errors in classification determination can directly lead to extended registration timelines, increased costs, or even refusal to accept the application. The most common mistakes include:

Directly copying the NMPA classification. Some companies assume a domestic Class III product is always high-risk overseas, but risk frameworks differ significantly by country and must be verified country by country.
Mixing CE and FDA classifications. CE classification is based on MDCG rules, while FDA classification uses Class I/II/III, and the two do not correspond directly. Misuse can affect intended use descriptions and evidence requirements.
Ignoring the independent classification of imaging software. Software accompanying imaging devices does not automatically belong to the device itself and may require separate classification, especially software with auxiliary diagnostic or automatic detection functions, which may be elevated to a higher risk class.
Underestimating the impact of AI modules on classification. AI software for imaging diagnosis is already considered an independent medical device or high-risk software in some countries. Companies need to consider AI functionality at the classification stage.
Neglecting the input of local agents. Classification determination cannot be done solely by headquarters; local agents are familiar with local regulatory interpretations, and skipping their input can lead to detours.
Failing to maintain classification decision records. Without written basis, later changes in regulatory personnel or agents make it impossible to explain to regulators why the product was classified in a particular way.

Company Preparation Checklist

To ensure the classification determination process runs smoothly, companies can follow the checklist below:

Establish a product regulatory dossier containing product name, model, hardware version, software version, intended use, and contraindications.
Designate a regulatory affairs lead to coordinate with the local agent and regulatory authorities.
Review the target country's current medical device regulations to confirm whether the product is a medical device.
Compare the target country's classification rules to preliminarily determine the risk class.
Collect registration certificates or classification decisions from global markets and create a comparison table.
Verify whether the quality management system meets ISO 13485 or MDSAP certification, as this affects regulatory confidence.
Review technical files to ensure they meet target-country requirements for labels, instructions, and language.
Sign a service agreement with the local agent, clearly defining responsibilities for classification, registration application, changes, and renewals.
Conduct registration pathway planning immediately after classification is determined, rather than confirming classification during the registration process.
Develop a contingency plan for classification changes if the regulatory authority raises a different classification opinion during review.

AIMEILI Regulatory Interpretation and Business Impact

As a regulatory consulting team with long-term experience in assisting companies with multi-country registrations, we have found that the most common misjudgment is treating classification as a one-time administrative issue rather than a regulatory decision that requires justification. Many companies do not invest time in classification research at project initiation and only learn of a classification mismatch after technical files are submitted, forcing a resubmission.

Therefore, classification pre-assessment and gap analysis should be performed early in the project. Companies should evaluate the target country's classification rules, product feature lists, and existing certificates together. Classification determination should not be left until the last minute, nor should it rely only on market feedback from the sales team. The most reliable approach is to involve a regulatory consultant familiar with local regulations and hold a classification meeting with the local agent during the project initiation phase.

What can be reused? ISO 13485 quality management system certificates, NMPA registration dossiers, and performance verification and risk management reports from CE technical files are generally referenceable. What must be localized? Intended use descriptions, labels and instructions, clinical evaluation summaries, and applicability assessments in risk analysis must be redrafted according to target-country regulations and cannot be simply translated.

Local agents and certificate control are critical. In many countries, certificates are held by the local agent. If the agent is uncooperative or changes mid-way, companies may face serious difficulties in modifications and renewals. Therefore, companies should pay close attention to agency agreements, clearly defining certificate ownership, change procedures, and renewal obligations. For multi-country registrations, centralized management of certificate validity, change status, and review timelines across all countries can significantly reduce the risk of duplicate documentation and corrective actions.

Business impact: A robust classification decision dramatically reduces registration delays and cost overruns. It also prevents the reputational damage of product detention or refusal. By treating the classification memorandum as part of the registration file rather than an internal discussion note, companies can quickly respond to regulator questions and keep the project on track. Investing two weeks to two months in classification at the beginning yields substantial savings in time and resources throughout the product lifecycle.

Frequently Asked Questions

Question: For the same product registered in multiple countries, will the classification always be the same?

Not necessarily. GHWP member states promote harmonization, but each country retains its own regulatory system. The same ultrasound device may appear as Class B in one country and Class C in another. Companies must confirm classification country by country and cannot assume one classification applies to all markets.

Question: How is the classification of AI software embedded in imaging devices determined?

It depends on whether the AI software independently influences clinical decisions. If AI only enhances images, it may not be classified as a standalone medical device. However, if AI is used for automatic detection, diagnostic suggestions, or risk assessment, it is likely to be considered standalone medical device software and may be assigned a higher risk class. Companies need to check whether the target country has special classification rules for AI software.

Question: How much time should be allocated for classification determination?

Depending on product complexity and the number of target countries, it generally takes two weeks to two months. If the target country has a pre-classification system, an inquiry can be submitted, but the waiting time may be longer. Companies should not compress this phase, as the cost of correction later is much higher.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI